Functional inhibition of PARG in pancreatic cancer cells, which has p53 pathway inactivation, enhanced the necrotic cell death after MMS treatment [29], suggesting that PARG could be a therapeutic target in certain types of cancer cells. The gene discussed is TP53; the disease is familial pancreatic carcinoma.